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During atherosclerosis monocyte-derived macrophages accumulate cholesteryl esters from low-density lipoproteins (LDLs)
via lectin-like oxidised LDL receptor-1 (LOX-1) and class AI and AII (SR-AI, SR-AII) and class B (SR-BI, CD36) scavenger
receptors. Here we examined the hypothesis that hyperglycaemia may modulate receptor expression and hence lipid accumulation
in macrophages. Human monocytes were matured into macrophages in 30 versus 5mM glucose and receptor expression
and lipid accumulation quantified. High glucose elevated LOX1 mRNA, but decreased SR-AI, SR-BI, LDLR, and CD36
mRNA. SR-BI and CD36 protein levels were decreased. Normo- and hyperglycaemic cells accumulated cholesteryl esters
from modified LDL to a greater extent than control LDL, but total and individual cholesteryl ester accumulation was not
aﬀected by glucose levels. It is concluded that, whilst macrophage scavenger receptor mRNA and protein levels can be
modulated by high glucose, these are not key factors in lipid accumulation by human macrophages under the conditions
examined.
1. Introduction
People with diabetes are at high risk of developing micro-
and macrovascular diseases, with cardiovascular disease
accounting for ca. 50% of deaths in these people [1]. Risk
factors for this enhanced atherosclerosis include chronic
elevated glucose (hyperglycaemia), insulin resistance,
dyslipidaemias, and haemostatic abnormalities [2]. Intensive
diabetes management can reduce cardiovascular events, with
most of the decreased risk being related to lower HbA1c
levels [3], consistent with hyperglycaemia being a major
contributing factor to diabetes-induced atherosclerosis. The
mechanism(s) by which this occurs have not been fully
elucidated [4]. Four principal processes have been proposed
to explain the role of hyperglycaemia in the vascular
complications of diabetes: increased polyol pathway flux;
increased protein glycation and glycoxidation; activation of
protein kinase C; increased hexosamine pathway flux [4].
Glycation involves the nonenzymatic reaction of glucose
or reactive aldehydes (e.g., methylglyoxal, glyoxal, glyco-
laldehyde) with amine (e.g., N-terminal or Lys side chain),
guanidine (Arg) and thiol (Cys) groups on proteins (e.g., the
apoliprotein B-100 component of LDL) and yields multiple
advanced glycation end products (AGEs) [5]. The rate and
extent of reaction are dependent on the concentration and
duration of exposure [5]. Reactive aldehydes, generated
from glucose, amino acid and lipid oxidation, or metabolic
pathways (e.g., via triosephosphates) [6], are present at
elevated levels in the plasma of people with diabetes [7],
and react with proteins much more rapidly than glucose
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[8, 9]. Free or protein-bound sugars also undergo autoxi-
dation (autooxidative glycosylation or glycoxidation) to give
radicals that can contribute to AGE generation.
A key step in atherosclerosis is the uptake of mod-
ified low-density lipoproteins (LDLs) by vascular wall
macrophages resulting in intracellular cholesterol accumu-
lation and formation of lipid-laden cells [10]. Native LDL
is internalised via LDL receptors in a tightly controlled
feedback-regulated manner [10]. In contrast, LDL modified
by multiple mechanisms, including oxidation, aggregation,
and glycation, is taken up in an uncontrolled manner
via multiple receptors, including lectin-like oxidised LDL
receptor-1 (LOX-1), scavenger receptors class AI and AII (SR-
AI and SR-AII), and class B scavenger receptors (SR-BI and
CD36) [11, 12].With regard to diabetes, glycation of LDL has
therefore been proposed to enhance atherosclerosis through
the promotion of lipid accumulation from LDL though
this is not universally agreed upon (reviewed in [13]). LDL
modification by methylglyoxal and glycolaldehyde ex vivo,
under conditions that minimise oxidation, results in lipid
accumulation by human monocyte-derived macrophages
(HMDMs) and murine macrophages [14, 15], with this
occurring primarily via SR-A and CD36 [15].
In addition to proatherogenic modifications to LDL,
changes in the number of receptors for these modified
particles, particularly the scavenger receptor types A and
B, CD36, and LOX-1 which are not subject to feedback
regulation, may also contribute to macrophage foam cell
formation. ApoE knockout mice deficient in SR-A or CD36
have been reported to have similar levels of atherosclerosis
to wild-type apoE knockout mice [16], whereas other studies
have demonstrated that deletion of these receptors decreases
atherosclerosis [17, 18]. Transgenicmice that overexpress SR-
A, have provided evidence for augmented cellular cholesteryl
ester accumulation from acetylated LDL [19]. In contrast,
LDL receptor knockout mice overexpressing bovine SR-A,
fed a “Western” diet, had reduced atherosclerosis [20], and
similarly mice over-expressing human SR-A exhibited no
changes in lesion area despite increased scavenger receptor
activity in vitro [21]. These changes have however been
reported principally in animal models, some of which did
not have a background of diabetes, and in systems where
the extent and type of lipoprotein modifications (both to
low- and high-density lipoproteins) are likely to be highly
heterogeneous and encompass both glycation and oxidation.
In the light of these conflicting data, this study exam-
ined whether maturation of human monocyte-derived
macrophages (HMDMs) in high (30mM) versus normal
(5mM) glucose results in elevated scavenger receptor mRNA
and proteins levels and enhanced cellular cholesterol and
cholesteryl ester accumulation from well-defined acetylated
or glycated LDL particles.
2. Research Design and Methods
2.1. LDL Isolation, Modification, and Protein Quantification.
LDL was isolated from multiple healthy, normoglycaemic,
male and female donors who were not taking any medica-
tions or vitamin supplements. This investigation conforms
with the principles outlined in the Declaration of Helsinki
and was approved by the Ethics Review Committee (RPAH
zone) of the Sydney South West Area Health Service (X05-
0232, X09-0013). The LDL was glycated or acetylated as pre-
viously [9, 14]; these protocols do not give rise to significant
oxidation of apoB protein, cholesterol, cholesteryl esters, or
antioxidants as assessed by HPLC with UV, fluorescence,
and electrochemical detection [9, 14]. Excess reagents were
removed by elution through PD10 columns (Amersham)
[9, 14]. LDL charge modification was quantified using
1% (w/v) agarose gels (Helena Laboratories) [14]. Protein
concentrations were quantified using the Bicinchoninic
Acid assay (Pierce) at 60◦C, with BSA as standard [14].
Solutions were prepared using Nanopure water (Millipore-
Waters) pretreated with washed Chelex-100 resin (Bio-Rad)
to remove trace transition metal ions, with the exception of
tissue culture reagents where sterile water (Baxter) was used.
2.2. Isolation and Culture of Human Monocyte-Derived
Macrophages (HMDMs). Monocytes were isolated from
white blood cell concentrates provided by the Australian
Red Cross Blood Service from healthy donors as described
previously [15]. Cells (1 × 106 in 1mL X-VIVO 10 medium;
BioWhittaker) were added to 12-well plates (Costar) and
allowed to adhere (1-2 h). After washing the monocytes
were incubated (5% CO2, 37◦C) for 9–11 days in RPMI
media (Sigma-Aldrich) containing 5 or 30mM glucose,
supplemented with 10% (v/v) heat-inactivated pooled
human serum, 2mM glutamine, and penicillin/streptomycin
(100U/mL and 100 μg/mL, resp.; BioWhittaker). After 4
days, the medium was changed every 2 days. The resultant
HMDMs were exposed to LDL (0 or 100 μg/mL, 48 h)
in RPMI media containing 10% (v/v) lipoprotein-deficient
serum (in place of human serum) and either 5 or 30mM glu-
cose. Medium was subsequently collected and the cells lysed
in water. Cell viability was assessed by lactate dehydrogenase
(LDH) release [14]. Cellular cholesterol and cholesteryl
esters were quantified, by mass, using HPLC [14]. Total
cholesterol values were taken as the sum of free cholesterol
and individual cholesteryl esters.
2.3. Assessment of HMDM Receptor Levels. Total RNA was
isolated using TRI reagent (Sigma-Aldrich), and 100 ng total
RNAwas reverse-transcribed in a 10 μL reaction using RNase
H+ MMLV reverse transcriptase (Bio-Rad). The mRNA
expression of the five genes of interest (SR-AI, SR-BI,
LDLR, CD36, LOX1) and a housekeeping gene(β-actin) was
determined by quantitative real-time PCR using iQ SYBR
Green Supermix (Bio-Rad) and 20 pmol each of forward and
reverse primer. The PCR conditions were as follows: 95◦C for
3mins, followed by 40 cycles of 95◦C for 30 s, 56◦C for 30 s,
and 72◦C for 30 s using the MyiQ Single-Color Real-Time
PCR Detection System (Bio-Rad). The primer sequences
were as follows: SR-AI (forward: 5′-TCACAATCAACAGGA-
GGACACT-3′ and reverse: 5′-CACGAGGAGGTAAAG-
GGCAAT-3′), SR-BI (forward: 5′-ACCGCACCTTCCAGT-
TCCAG-3′ and reverse: 5′-ATCACCGCCGCACCCAAG),
LDLR (forward: 5′-CCCAGCGAAGATGCGAAGATAT-3′
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and reverse: 5′-GGTGAAGAAGAGGTAGGCGATG-3′),
CD36 (forward: 5′-TGCTGTCCTGGCTGTGTT-3′ and
reverse: 5′-TGTTGCTGCTGTTCATCATCA-3′), LOX1
(forward: 5′-CTGGCTGCTGCCACTCTA-3′ and reverse:
5′-TTGCTTGCTCTTGTGTTAGGA-3′), and β-actin (for-
ward: 5′-GAATTCTGGCCACGGCTGCTTCCAGCT-3′ and
reverse: 5′-AAGCTTTTTCGTGGATGCCACAGGACT-3′).
Relative changes in mRNA levels of the genes of interest were
normalized using the ΔΔCT method to β-actin after using
GENorm (http://medgen.ugent.be/∼jvdesomp/genorm/) to
assess that this was the most stable reference gene for this set
of experiments.
Protein was extracted from cells using RIPA buﬀer
(150mMNaCl, 1.0% w/v Igepal CA-630, 0.5% w/v deoxy-
cholate, 0.1% w/v SDS, 50mMTris, pH 8.0; Sigma-Aldrich)
and assayed for protein levels. Equal amounts of total cell
lysate protein (100 μg) were run on each gel. Samples were
denatured by heating at 95◦C for 5mins with sample loading
buﬀer containing β-mercaptoethanol. Denatured proteins
were resolved by SDS-PAGE (10%w/v acrylamide) then
transferred for 1 h at 13V to polyvinyl difluoride membranes
(Millipore), blocked using 5% (w/v) skim milk in TBST
(50mMTris/HCl, 150mMNaCl, 0.1 % v/v Tween 20; pH
7.5), washed three times with TBST, and incubated overnight
with SR-AI antibody at 1 : 600 dilution (ab53566, Abcam),
SR-BI antibody at 1 : 500 dilution (ab74413, Abcam), LDLR
antibody at 1 : 200 dilution (ab30532, Abcam), LOX1 anti-
body at 1 : 500 dilution (ab60178, Abcam), or with β-actin
antibody at 1 : 2000 dilution (MAB1501R, Chemicon). For
the CD36 antibody, the blots were blocked using 3% (w/v)
BSA in TBST overnight, followed by a 2-hour incubation at
21◦C with CD36 antibody (ab36977, Abcam) at a dilution
of 1 : 10,000. The membrane was then washed three times
with TBST and incubated with the corresponding secondary
antibody conjugated to horseradish peroxidase (HRP) at
a 1 : 10,000 dilution for 2 h at 21◦C. The membrane was
again washed three times with TBST, and immunodetec-
tion was accomplished with enhanced chemiluminescence
(Amersham Biosciences). Membranes were directly digi-
tised (ChemiDoc XRS, Bio-Rad) and densitometric analysis
completed using Quantity One Software (Bio-Rad). Normal
glucose values were set as 100% to allow changes relative to
this concentration to be determined.
2.4. Statistical Analyses. Data are mean + SEM from ≥3
separate experiments with triplicate samples, unless noted
otherwise. Statistical analysis was performed with one-way
analysis of variance (ANOVA) and Newman-Keul’s post hoc
analysis, except for the receptor levels that were analysed
using a nonpaired, two-tailed Student’s t-test. Significance
was assumed if P < 0.05.
3. Results
3.1. Diﬀerentiation of Human Monocytes under Normal
versus High Glucose Concentrations. Incubation of freshly
elutriated human monocytes in 5 or 30mM glucose for 9–
11 days gave rise to macrophage cells (HMDMs) as reported
previously [22]. The 30mM glucose concentration did not
give rise to morphological changes or significant diﬀerences
in LDH release or protein levels (data not shown).
3.2. Eﬀect of Normal versus High Glucose Concentrations on
Receptor mRNA and Protein Levels. Maturation of HMDM
(in the absence of any exposure to LDL) in 30mM compared
to 5mM glucose significantly decreased the expression (as
assessed by real-time quantitative PCR) of SR-AI mRNA (79
+ 4 versus 100 + 6%), SR-BI (42 + 2 versus 100 + 7%),
LDLR (55 + 4 versus 100 + 6%), and CD36 (77 + 4% versus
100 + 3%) (Figure 1). In contrast, the expression of LOX1
was significantly increased (340 + 18% versus 101 + 5%)
by 30mM compared to 5mM glucose (Figure 1). Receptor
expression was also assessed at the protein level by Western
blotting (Figure 2). Exposure to 30mM glucose significantly
decreased the protein expression of SR-BI (9 + 1% versus
100 + 8%) and CD36 (82 + 4% versus 100 + 3%) with a
trend towards a decrease in SR-AI expression (87 + 6% versus
100 + 4%) when compared to the 5mM glucose condition.
In contrast, there was a trend towards an increase in the
expression of both LDLR (114 + 6% versus 100 + 8%) and
LOX1 (198 + 52% versus 100 + 1%) (Figure 2).
3.3. Generation of Acetylated and Glycated LDL. Acetylated
(AcLDL) and glycated LDL (using methylglyoxal, MGO, or
glycolaldehyde, GA) were generated from native LDL. The
extent of modification to LDL induced by these protocols,
including loss of Lys, Arg, and Trp residues, extent of
aggregation, changes in mobility, the (minimal) extents of
oxidation of apoB protein, cholesterol, cholesteryl esters, and
consumption of antioxidants, has been reported previously
[9, 14]. Modification was confirmed by quantification of
the relative electrophoretic mobilities (REMs) of the treated
particles compared to native LDL (nLDL; Figure 3). The
AcLDL and glycated LDL preparations were statistically
diﬀerent to the incubation control (LDL incubated with
EDTA), whilst the latter was not statistically diﬀerent to
nLDL. These data are in accord with our previously reported
levels [9, 14]. The REMs of LDLs treated with 50 versus
100mM glycolaldehyde were not statistically diﬀerent.
3.4. Lipid Loading of HMDM Matured in Normal or High
Glucose by Acetylated or Glycated LDL. HMDMs, incubated
in normal or high glucose, were exposed to AcLDL, highly
glycated LDL, or control LDL (LDL incubated with EDTA
to prevent oxidation) for 48 h. No diﬀerences were detected
in cell morphology or number, LDH release or cell protein
levels (data not shown). A significant increase in total
cholesterol was detected for HMDM incubated with AcLDL
for 48 h, compared to control cells not exposed to LDL (314
± 60 versus 73 ± 9 nmol/mg cell protein for cells in 5mM
glucose; 263 ± 42 versus 77 ± 8 nmol/mg cell protein for
cells in 30mM glucose; Figure 4). Cholesterol accumulation
from AcLDL for the 5 versus 30mM glucose concentrations
was not significantly diﬀerent. Similar data were observed for
cholesteryl esters when expressed as mass or as a percentage
(AcLDL versus control: 210 ± 57 versus 5 ± 1 nmol/mg cell
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Figure 1: Gene expression data for (a) SR-AI, (b) SR- BI, (c) LDLR, (d) LOX1, and (e) CD36 from HMDM matured in either 5mM (white
bars) or 30mM glucose (black bars) as measured by real-time quantitative PCR. Data (mean + SEM from n = 3 independent experiments)
are expressed as a percentage change from the 5mM concentration, which was set as 100%. ∗P < 0.05 for the 30mM glucose concentration
versus the 5mM, using two-tailed unpaired t-tests.
protein for 5mMglucose; 136± 18 versus 3± 1 nmol/mg cell
protein for 30mM glucose; Figure 4), with no significant dif-
ferences between the two glucose concentrations, for either
AcLDL or control. There were no significant diﬀerences in
the type or concentration of individual cholesteryl esters
present in the cells (data not shown).
Incubation of either population of HMDM with LDL
modified with 10mM glycolaldehyde (GA(10mM)-LDL) for
48 h did not have any significant eﬀect on total cholesterol
or cholesteryl ester mass or proportion of total cholesterol
present as esters, compared to control cells. Incubation
of HMDM with LDL preglycated with 50 or 100mM
glycolaldehyde resulted in a significant increase in cholesterol
and cholesteryl ester levels compared to cells incubated with
no LDL, control LDL (EDTA-LDL) or GA(10mM)-LDL
(Figure 5). There were no significant diﬀerences in the extent
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Figure 2: Protein levels (mean + SEM from n = 3 independent experiments) for (a) SR-AI, (b) SR-BI, (c) LDLR, (d) LOX1, and (e)
CD36 from HMDM matured in either 5mM (white bars) or 30mM glucose (black bars), expressed as a percentage change from the 5mM
concentration (set as 100%). (f) Representative Western immunoblots (from three independent experiments) of 5mM (NG) and 30mM
(HG) samples. ∗P < 0.05 for the 30mM concentration versus the 5mM using two-tailed unpaired t-tests.
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Figure 3: Relative electrophoretic mobility (REM) of unmodified
(native) LDL (set as 1), LDL incubated with EDTA (EDTA-LDL),
acetylated LDL (AcLDL), and LDL glycated by reactive aldehy-
des (glycolaldehyde, GA; methylglyoxal, MGO) at the indicated
concentrations. Letters above bars indicate statistically significant
diﬀerences at the P < 0.05 level for the following comparisons: “a”
compared to native-LDL; “b” compared to EDTA-LDL; “c” com-
pared to Ac-LDL; “d” compared to GA(10mM)-LDL; “e” compared
to GA(50mM)-LDL; “f” compared to GA(100mM)-LDL.
of cholesterol or cholesteryl ester accumulation between the
5 or 30mM glucose conditions for the LDL glycated with 50
or 100mM glycolaldehyde (Figure 5). There were no signi-
ficant diﬀerences in the types or concentrations of cellular
cholesteryl esters.
HMDM incubated with LDL modified with 100mM
MGO, no LDL, or control LDL (EDTA-LDL) contained 109
± 13, 76 ± 6, and 88 ± 2 nmol total cholesterol/mg cell pro-
tein, respectively, for the 5mM glucose concentration, and 89
± 13, 60 ± 8, and 80 ± 8 nmol total cholesterol/mg cell pro-
tein for the 30mM glucose concentration, respectively. These
values were not significantly diﬀerent. Similarly, no statistical
diﬀerences were observed for cellular cholesteryl ester mass
and percentage of cholesterol esterification between the
diﬀerent conditions or for the types or concentrations of the
individual cholesterol esters (data not shown).
4. Discussion
In this study the eﬀect of maturation of HMDM in 30
versus 5mM glucose on the accumulation of cholesterol
and cholesteryl esters from well-characterized acetylated or
highly glycated LDL has been examined. A glucose concen-
tration of 30mMwas chosen as this reflects the limit detected
in people with diabetes, compared to normal levels of ∼
5mM. The cells were exposed to these glucose concentra-
tions throughout the maturation period from monocytes to
macrophages. Previous studies have shown that exposure of
HMDM (and other macrophage cells) to glycated, but min-
imally oxidised, LDL results in a time- and concentration-
dependent accumulation of cholesterol and cholesteryl esters
[14, 15], and these data have been confirmed here. This
accumulation, which occurs primarily via modified LDL
uptake via SR-AI and CD36 [15], is dependent on the nature
and extent of LDL modification. MGO and GA induced a
more rapid and extensive modification of LDL than glucose
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Figure 4: Eﬀect of maturation in 5 versus 30mM glucose on the
accumulation of total cholesterol (a) and cholesteryl esters (b) and
percentage cholesteryl esters (c), quantified by mass using HPLC,
in HMDM cells after exposure to acetylated LDL (black bars) or
control (no LDL, white bars). Data are mean ± SEM from four
independent experiments. ∗P < 0.05, using one-way ANOVA and
Newman-Keuls multiple comparison test. No diﬀerences between
HMDM matured in normal and high glucose concentrations were
observed for any of the data.
and a subsequent greater lipid accumulation within the
HMDM than glucose-modified LDL [14, 15, 23, 24].
High glucose concentrations have been reported to
enhance the levels of CD36, SR-A, and LOX-1 receptors
involved in LDL internalisation [25–27], and the role of
these receptors in the development of atherosclerosis is well
established [16–20, 28]. The majority of these studies have
not however used well-characterised lipoprotein particles,
so the role of LDL particle modification (and the extent
of this process) in mediating lipid accumulation cannot be
discerned. Contrary to previous findings, we have demon-
strated that expression of these receptors was, with the
exception of LOX-1, inhibited when human monocytes were
diﬀerentiated under high glucose conditions. However, with
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Figure 5: Eﬀect of maturation in 5 versus 30mM glucose on the
accumulation of total cholesterol (a), cholesteryl esters (b) and
percentage cholesteryl esters (c), quantified by mass using HPLC, in
HMDM cells after exposure to native LDL (white bars), incubation
control LDL (LDL incubated with EDTA: EDTA-LDL, gray bars),
or modified LDL preglycated with 10 (black bars), 50 (striped bars)
or 100mM (hatched bars) glycolaldehyde. Data are mean ± SEM of
three or more experiments. ∗P < 0.05, and #P < 0.05 as compared
to other treatments, using one-way ANOVA and Newman-Keuls
multiple comparison test.
the exception of CD36, the modulation of gene expression
was not matched with significant changes in synthesis of the
same receptors or lipid accumulation. These data indicate
that there may be significant posttranslational controls on
receptor protein concentrations and compensatory changes
that oﬀset the altered level of uptake mediators. This may
include changes in receptor half-life and traﬃcking.
Lipid accumulation by HMDM (which reflects the bal-
ance betweenmultiple processes including uptake and eﬄux)
has been quantified using known amounts of well-defined
highly glycated (but not significantly oxidised) LDL particles.
These particles were prepared using threemethods which not
only generated particles with markedly diﬀerent patterns and
extents of LDL alteration, but which also ensured particle
homogeneity and minimised oxidation as a potential lim-
iting and variable factor. Acetylation increases the negative
charge of LDL particles via conversion of Lys residues to
N-acetylated species with a corresponding loss of positive
charge [29]. In contrast, glycolaldehyde targets Lys, Arg, and
Trp residues, with Lys modified to a greater extent than
Arg or Trp, while methylglyoxal preferentially modifies Arg
residues [5, 14, 23, 30, 31]. The extent of change in particle
charge (as judged by relative electrophoretic mobility) was
comparable between acetylated and glycolaldehyde-modified
LDL and greater than for methylglyoxal-modified LDL. In
contrast to the major changes induced to LDL by these reac-
tive aldehydes, previous studies have shown that exposure of
LDL to high glucose concentrations (≤ 100mM) for similar
periods did not induce significant alterations (see, e.g., [9]).
The eﬀects of diﬀerent glycolaldehyde concentrations
used in the LDL modification have been examined, to
determine whether lipid accumulation is dependent on the
degree of LDL modification. No significant diﬀerences were
detected between the 30 and 5mM glucose-exposed cells
with any of these LDL preparations, though the extent of
accumulation was less marked with LDL modified with
10, versus 50 or 100mM glycolaldehyde. These data are
consistent with the receptor level not being a critical factor
in determining the extent of lipid accumulation. In contrast,
the degree of particle modification is a major factor. Whether
the rate of lipid accumulation is aﬀected by altered receptor
expression has not been examined in detail. However,
exposure of macrophages to modified LDL in vivo is likely to
occur throughout the lifetime of the monocyte/macrophage,
so the kinetics of LDL uptake may not be the major
determinant of the extent of loading relative to the impact
of the nature and extent of LDL modification.
These data appear to contradict a previous report where
increased lipid loading was detected in cells exposed to high
glucose [27]. However, it should be noted that diﬀerent
methods were employed to quantify lipid loading, with mass
measurement used in the current study, and radiotracers in
the previous study. The latter technique demonstrated a 40%
increase in 3H-oleate incorporation into cholesteryl esters
under hyperglycaemic conditions, rather than a net increase
in total cholesterol mass. Previous studies have indicated
that oleate incorporation into esters may not correlate
directly with total cellular cholesterol accumulation in some
macrophages [32]. Thus methodology and experimental
design may account for this discrepancy.
Glycolaldehyde and methylglyoxal were used to generate
the glycated LDL, in place of glucose, as these species are
much more reactive than glucose allowing for the generation
of modified particles within a time frame consistent with
the relatively short plasma half-life of LDL; glucose induces
LDL modification at a much lower rate [9, 33]. Elevated,
8 Experimental Diabetes Research
though variable, levels of reactive aldehydes, including
methylglyoxal, have been detected in plasma from people
with diabetes compared to healthy controls [7, 33, 34].
The high reactivity of these aldehydes [35] with Arg,
Lys, His, and Cys side-chains and the N-terminal amino
group, clearly limits the concentration of these materials in
plasma. These reported values therefore represent steady-
state concentrations, rather than the overall flux to which a
protein may be exposed over its lifetime in vivo, given the
short half-life (minutes) of reactive aldehydes in plasma [35].
The (high) bolus doses employed in the current study (and
also by other groups; e.g., [36–39]) were chosen to model
such lifetime exposure. Whether these steady-state plasma
levels of aldehydes reflect those within cells is unclear, as no
specific cellular measurements have been reported. Several
processes have been identified, within the vessel wall, that
have the potential to generate high levels of these aldehydes
including intracellular production and decomposition of
triose phosphates, glucose autooxidation [40], inflammation
[41–43], and lipid oxidation [44]. These data suggest that
higher levels of reactive aldehydes are likely to be present in
atherosclerotic lesions, than in plasma, and potentially play a
role in the macrovascular complications of diabetes.
This study has a number of limitations. Primary human
monocyte-derived macrophages have been used in place of
tissue macrophages due to the diﬃculty in obtaining the
latter from donors. Furthermore, the cells were exposed to
a constant glucose concentration, in contrast to the variable
levels seen in vivo. The LDL used in this study was glycated
in vitro, rather than using in vivo glycated materials, as
this allows well-defined particles to be employed and at
concentrations suﬃcient to ensure that the results were not
confounded by the variable types and levels of modification
observed in vivo.
In conclusion, this study suggests that changes to cellular
receptor levels induced by chronic exposure of cells to high
glucose do not significantly modulate cellular cholesterol
and cholesteryl ester accumulation, or cholesterol ester type,
by human macrophages. This was true despite significant
changes in the expression of receptor mRNA and protein
levels induced by high glucose concentrations. These data
support hyperglycaemia-induced protein glycation (e.g., of
lipoproteins) as being a major underlying cause for the
increased incidence, and rate of development, of atheroscle-
rosis in people with diabetes.
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